

DAFTAR PUSTAKA

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7-30.
2. Indonesia KKR. Pusat Data dan Informasi Kementerian Kesehatan RI Stop Kanker. Jakarta: Kementerian Kesehatan Indonesia; 2015.
3. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao JJCb, et al. Breast cancer: epidemiology and etiology. 2015;72(2):333-8.
4. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. 2015;373(3):209-19.
5. Anderson WF, Chatterjee N, Ershler WB, Brawley OWJBcr, treatment. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. 2002;76(1):27-36.
6. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. 2011;103(6):470-7.
7. Coates AS, Members P, Winer EP, Members P, Goldhirsch A, Members P, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Annals of Oncology.* 2015;26(8):1533-46.
8. Jatoi I, Proschan MAJAJoco. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. 2005;28(3):289-94.
9. Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens M-R, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. 2012;13(4):412-9.
10. Anampa J, Makower D, Sparano JAJBM. Progress in adjuvant chemotherapy for breast cancer: an overview. 2015;13(1):195.
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman DJCacjfc. Global cancer statistics. 2011;61(2):69-90.
12. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. 2007;99(4):272-82.
13. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. 2015;26(8):1533-46.
14. Mirossay L, Varinská L, Mojžiš JJIjoms. Antiangiogenic effect of flavonoids and chalcones: An update. 2018;19(1):27.
15. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. 2016;66(1):43-73.

16. Faried A, Bolly HMB, Septiani L, Kurnia D, Arifin MZ, Wirakusumah FFJEJMP. Potential of Indonesian herbal medicine, *Phaleria Macrocarpa* (Scheff.) boerl, for targeting multiple malignancy signaling pathways: an introductory overview. 2016;11(2):1-17.
17. Chouhan A, Karma A, Artani N, Parihar DJWJOP, Sciences P. Overview on cancer: role of medicinal plants in its treatment. 2016;5(5):185-207.
18. Rady I, Bloch MB, Chamcheu R-CN, Banang Mbeumi S, Anwar MR, Mohamed H, et al. Anticancer Properties of *Graviola* (*Annona muricata*): A Comprehensive Mechanistic Review. 2018;2018.
19. Badrie N, Schauss AG. Soursop (*Annona muricata* L.): composition, nutritional value, medicinal uses, and toxicology. *Bioactive foods in promoting health*: Elsevier; 2010. p. 621-43.
20. Baillon H. *Histoire des plantes: Tome premier... Dessins de Faguet*: Librairie Hachette; 1869.
21. SAD T, TEJASARI M. *Gardnerella vaginalis* ATCC 14018 resistant to metronidazol and soursop leaves (*Annona Muricata* Linn) preparation. 2016.
22. Kumar V, Abbas AK, Aster JC. *Robbins basic pathology e-book*: Elsevier Health Sciences; 2017.
23. Longo D. *Harrison's hematology and oncology, 2e*: McGraw-Hill Publishing; 2013.
25. Mardiana L, Ratnasari J. *Ramuan dan khasiat sirsak*: Penebar Swadaya Grup; 2011.
26. Adrian K. *Waspada! Efek Samping Daun Sirsak sebelum Konsumsi Ekstraknya*. 2019.
27. Moghadamtousi S, Fadaeinasab M, Nikzad S, Mohan G, Ali H, Kadir HJJjoms. *Annona muricata* (Annonaceae): a review of its traditional uses, isolated acetogenins and biological activities. 2015;16(7):15625-58.
28. Panche A, Diwan A, Chandra SJJons. *Flavonoids: an overview*. 2016;5.
29. Xiang L, Yi X, Wang Y, He XJSr. Antiproliferative and anti-inflammatory polyhydroxylated spirostanol saponins from *Tupistra chinensis*. 2016;6:31633.
30. Yildirim I, Kutlu TJIJBC. Anticancer agents: saponin and tannin. 2015;9:332-40.
31. Xu X-H, Li T, Fong C, Chen X, Chen X-J, Wang Y-T, et al. Saponins from Chinese medicines as anticancer agents. 2016;21(10):1326.
32. Chen M-F, Huang SJ, Huang C-C, Liu P-S, Lin K-I, Liu C-W, et al. Saikosaponin d induces cell death through caspase-3-dependent, caspase-3-independent and mitochondrial pathways in mammalian hepatic stellate cells. 2016;16(1):532.
33. Cheng G, Gao F, Sun X, Bi H, Zhu YJMmr. Paris saponin VII suppresses osteosarcoma cell migration and invasion by inhibiting MMP2/9 production via the p38 MAPK signaling pathway. 2016;14(4):3199-205.
34. Zhao P, Song S, Du L, Zhou G, Ma S, Li J, et al. Paris Saponins enhance radiosensitivity in a gefitinibresistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest. 2016;13(3):2878-84.

35. Cai Y, Zhang J, Chen NG, Shi Z, Qiu J, He C, et al. Recent advances in anticancer activities and drug delivery systems of tannins. 2017;37(4):665-701.
36. McLaughlin JLJoNP. Paw paw and cancer: annonaceous acetogenins from discovery to commercial products. 2008;71(7):1311-21.
37. Waller DG, Sampson T. Medical pharmacology and therapeutics E-Book: Elsevier Health Sciences; 2017.
38. Katzung BG, Trevor AJ. Basic & clinical pharmacology: McGraw-Hill New York, NY; 2015.
39. Susanto A, Nasihun T, Husaana AJSMJKdK. Soursop (*Annona Muricata*, Linn) Leaf Ethanol Extract Cream Application Affected the Expression of TNF- α and VEGF on Balb/C Mice Skin Exposed to Acute UVB. 2018;9(2):73-7.
40. Handayani SI, Rahmadi L, Prasasty VDJB, Journal P. Molecular Docking and Drug-Likeness for the Identification of Inhibitory Action of Acetogenins from *Annona Muricata* as Potential Anticancer Against Hypoxia Inducible Factor 1 Alpha. 2018;11(3):1301-7.
41. Syed DN, Adhami VM, Khan N, Khan MI, Mukhtar H, editors. Exploring the molecular targets of dietary flavonoid fisetin in cancer. Seminars in cancer biology; 2016: Elsevier.
43. Maria IL, Sainal AA, Nyorong MJMKMIUH. Risiko Gaya Hidup terhadap Kejadian Kanker Payudara pada Wanita. 2017;13(2):157-66.
44. Elaimy AL, Mercurio AMJSS. Convergence of VEGF and YAP/TAZ signaling: Implications for angiogenesis and cancer biology. 2018;11(552):eaau1165.
45. Agu KC, Okolie NP, Falodun A, Erharuyi O, Igbe I, Elekofehinti OO, et al. Isolation and Elucidation of 15-Acetylguanacone from Soursop (*Annona muricata* Linn) Fruit and Molecular Docking Experiments. 2017;21(2):236-43.
46. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock REJCr. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. 2002;62(7):2034-42.
47. Burridge PW, Li YF, Matsa E, Wu H, Ong S-G, Sharma A, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. 2016;22(5):547.
48. McKenna MT, Weis JA, Barnes SL, Tyson DR, Miga MI, Quaranta V, et al. A predictive mathematical modeling approach for the study of doxorubicin treatment in triple negative breast cancer. 2017;7(1):5725.
49. Lindner DJ, Borden ECJijoc. Effects of tamoxifen and interferon- β or the combination on tumor-induced angiogenesis. 1997;71(3):456-61.
50. McNamara D, Harmey J, Wang J, Kay E, Walsh T, Bouchier-Hayes DJEJoSO. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. 2001;27(8):714-8.
51. Kim M, Shin H. Abstract P4-14-13: Tamoxifen induced ovarian hyperstimulation during hormonal therapy for breast cancer. AACR; 2019.

52. Kiyotani K, Mushiroda T, Sasa M, Bando Y, Sumitomo I, Hosono N, et al. Impact of CYP2D6* 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. 2008;99(5):995-9.

